CLINICAL TRIALS PROFILE FOR LEUKERAN
✉ Email this page to a colleague
All Clinical Trials for Leukeran
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00875667 ↗ | A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Completed | Celgene | Phase 2 | 2009-04-30 | To evaluate the safety and efficacy of lenalidomide versus investigator choice in patients with relapsed or refractory mantle cell lymphoma. |
| NCT00875667 ↗ | A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) | Completed | Celgene Corporation | Phase 2 | 2009-04-30 | To evaluate the safety and efficacy of lenalidomide versus investigator choice in patients with relapsed or refractory mantle cell lymphoma. |
| NCT00910910 ↗ | Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial) | Completed | Celgene | Phase 3 | 2009-10-13 | The purpose of this study is to determine the safety and efficacy of lenalidomide as a first line therapy in treating patients with B-cell Chronic Lymphocytic Leukemia. This study will compare the effects (good and bad) of lenalidomide with chlorambucil. |
| NCT00910910 ↗ | Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial) | Completed | Celgene Corporation | Phase 3 | 2009-10-13 | The purpose of this study is to determine the safety and efficacy of lenalidomide as a first line therapy in treating patients with B-cell Chronic Lymphocytic Leukemia. This study will compare the effects (good and bad) of lenalidomide with chlorambucil. |
| NCT01088048 ↗ | Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or | Completed | Gilead Sciences | Phase 1 | 2010-03-25 | The primary objective of the study is to evaluate the safety of idelalisib in combination with an anti-CD20 monoclonal antibody (mAb), a chemotherapeutic agent, a mammalian target of rapamycin (mTOR) inhibitor, a protease inhibitor, an antiangiogenic agent, and/or an immunomodulatory agent in participants with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL). |
| NCT01657955 ↗ | Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia | Unknown status | Shandong Lanjin Pharmaceuticals Co.,Ltd | Phase 3 | 2011-01-01 | The purpose of this study is to determine whether bendamustine is effective in the treatment of initial treatment of Chronic Lymphocytic Leukemia (CLL). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Leukeran
Condition Name
Clinical Trial Locations for Leukeran
Trials by Country
Clinical Trial Progress for Leukeran
Clinical Trial Phase
Clinical Trial Sponsors for Leukeran
Sponsor Name
